API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Alaunos intends to use the net proceeds from the offering to fund the continued development of the product candidates in its pipeline, and for working capital, capital expenditures and general corporate purposes.
Lead Product(s): Ad-RTS-hIL-12,Veledimex,Cemiplimab
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $15.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2022
Details:
Interim data from the phase 2 study of Controlled IL-12 and cemiplimab combo to treat rGBM, updated interim data from the phase 1 study of Controlled IL-12 and nivolumab for rGBM, and data from phase 1/2 study of Controlled IL-12 monotherapy to treat DIPG to be presented.
Lead Product(s): Ad-RTS-hIL-12,Veledimex,Cemiplimab
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
The open label, single cohort Phase 1/2 clinical trial is evaluating the safety of FCX-013 as its primary objective. Secondary objectives include assessments of fibrosis at targeted sclerotic lesions at various time points through 26 weeks post-administration of FCX-013.
Lead Product(s): FCX-013,Veledimex
Therapeutic Area: Dermatology Product Name: FCX-013
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
FDA has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational treatment of diffuse intrinsic pontine glioma (DIPG), a lethal brain tumor occurring in the pontine region of the brain.
Lead Product(s): Ad-RTS-hIL-12,Veledimex
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2020
Details:
The phase 1/2 trial is designed to evaluate the safety and tolerability of a single intratumoral injection of Ad-RTS-hIL-12 given with up to 14 days of oral veledimex in children with gliomas.
Lead Product(s): Ad-RTS-hIL-12,Veledimex
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2020
Details:
Ziopharm’s Controlled IL-12 platform is an investigational gene therapy designed to induce and control the production of human interleukin 12 (hIL-12), a master-regulator of the immune system.
Lead Product(s): Ad-RTS-hIL-12,Veledimex,Cemiplimab
Therapeutic Area: Oncology Product Name: Ad-RTS-hIL-12
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile.
Lead Product(s): Ad-RTS-hIL-12,Veledimex
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Ziopharm Oncology to present data on Ad-RTS-hIL-12 plus veledimex, both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) for the treatment of recurrent glioblastoma.
Lead Product(s): Ad-RTS-hIL-12,Veledimex,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020